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Abstract
T-cell development from multipotent progenitors to specialized effector subsets of mature T cells
is guided by the iterative action of transcription factors. At each stage, not only do transcription
factors interact with an existing landscape of histone modifications and nucleosome packing, but
they also interact with other bound factors and modify the landscape for later-arriving factors, in
ways that fundamentally affect the control of gene expression. This review covers insights from
genome-wide analyses of transcription factor binding and resulting chromatin conformation
changes that reveal roles of cytokine signaling in effector T-cell programming, the ways one factor
can completely transform the impacts of previously bound factors, and the ways that the baseline
chromatin landscape is established during early T-cell lineage commitment.
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Complex developmental processes and transcription factor guidance
Lymphocytes develop from multipotent stem cells through a hierarchical process in which
the spectrum of accessible cell fates is progressively narrowed, even as the cells become
armed with an increasing kit of expressed effector genes (reviewed in [1–6]). This
differentiation program is actually the output of four kinds of processes, operating
repeatedly at a series of choice points: (1) new regulatory gene activation, (2) selective
earlier regulatory gene silencing, (3) combinatorial use of previously expressed and newly
expressed regulatory factors across the genome, and (4) changing patterns of accessibility of
cis-regulatory elements for transcription factor binding in general, as a result of past and
ongoing regulatory events. These interlaced gene regulation changes underlie the whole
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history of any given CD4+ effector T-cell from its origin in totipotent embryonic cells,
through specification as a hematopoietic stem cell that can give rise to all possible blood cell
types, eventually through a committed T-cell precursor that can still generate multiple
classes of T cells, through a choice between helper and killer fates in the thymus, and finally
through a post-thymic choice of alternative effector fates[7–14]. By the end, the cell is
finally primed for expression of the right combination of cytokines and signal receptors to
play its appropriate role in the immune response, although this last effector choice remains
somewhat plastic under variable physiological conditions[10, 15–17]. However, all the
earlier choices that establish a T-cell identity are durable. The way that present gene
regulatory mechanisms set up opportunities for future gene expression while removing the
conditions needed for past gene expression gives the program its hierarchical, one-way
character. With the advent of new technologies for visualizing the interaction of
transcription factors with DNA and the local consequences of that binding for regulatory
sequence activity, a wealth of new insights into this complex process have emerged. This
review looks at exciting implications of recent discoveries for the prospect of understanding
lymphocyte development as a whole at a causal, molecular level.
Sequence-specific DNA recognition gives transcription factors the primary responsibility as
readers of the regulatory genetic code, and this is particularly important in any
developmental process. If a cell needs to change its gene expression pattern, it must use the
combined activities of the transcription factors it expresses to mark out the right new regions
of the genome for transcriptional activation or to signal specific, previously active regions to
become inactive. This is not a role that can be substituted by histone modification reader/
writers that simply propagate a chromatin state irrespective of sequence, nor by passively
replicated CpG methylation patterns. At each stage in a developmental process, as new
transcription factors are expressed, they can bind to previously empty regulatory sites with
consequences that affect the activity of cis-regulatory elements like promoters and
enhancers[18–23].
A valuable shortcut toward understanding lymphocyte development has been the
identification of a few transcription factors that have potent, essential functions in the
emergence of particular cell types. They achieve their impact not only through direct
regulation of effector genes but also through positive and negative cross-regulation of
collaborating and antagonistic factors, respectively, in a gene regulatory network. EBF1 and
Pax5 are powerful regulators of B-cell development, Th-POK (Zbtb7b) is a powerful
regulator of CD4+ T cell development, whereas for effector subtype specialization of CD4+
T cells, T-bet, GATA-3, RORγt and Foxp3 are the signature regulators of Th1, Th2, Th17,
and Treg cells, respectively (rev. in [9, 24–26]).
Analogously PU.1 and C/EBP family factors dominate myeloid cell development[27]. These
central lineage-regulatory factors have attracted much attention because of their influence,
and are often referred to as “master” regulators (see Box 1). In detail, however, the causal
links through which any transcription factor brings about a transformation of cellular
function depend on system aspects besides the transcription factor’s own ability to recognize
its target sites in genomic sequence. The choice of sites to bind, and the possible effects
exerted when the factor binds there, are dependent both on the current accompanying
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presence of other transcription factors and on the history of the cell’s prior regulatory states.
Understanding what actually happens at a developmental choice is more interesting than a
simple regulatory command.
Box 1
Beyond the “Master regulator” concept
The roles of EBF1 and Pax5 in B cell development provided a strong prototype for
powerful central lineage regulators (reviewed by [26]). These are both specific for B
cells, expressed only in B-lineage cells among all hematopoietic lineages; they are both
essential for B cell development; they both directly activate B-cell genes; and they can
both antagonize development to non-B cell fates. By simply focusing on the requirements
for activating these two transcription factors and the activities of these two factors on
their targets, an immense amount of insight into B-cell development has been gained.
However, at the mechanistic level, EBF1 and Pax5 work collaboratively with other
transcription factors such as E2A, which is not B-cell specific. The same requirement for
combinatoriality tempers the roles of all “master regulator” candidates[9, 24, 25].
This is particularly true for the CD4+ T cell subset regulatory factors, GATA-3, T-bet,
RORγt, and Foxp3. In each cell type these factors must collaborate with STAT or Smad
transcription factors activated by appropriate cytokine receptor stimulation in order to
work. Furthermore, despite their lineage-specific roles in late T-cell effector
differentiation, expression of GATA-3, T-bet (Tbx21), and RORγt (Rorc) is not specific
to the CD4+ T-cell lineage programs in which they predominate. T-bet is a prominent
regulator in NK cells, iNKT cells, and CD8+ T cells as well as Th1 CD4+ cells, where at
least its roles as a positive regulator for IFNγ expression may be conserved. However,
GATA-3 and RORγt have crucial earlier stages of expression that affect the fate of all αβ
T-cell precursors, clearly regulating different sets of genes than the Th2 and Th17
programs. Turned on in the first wave of T-cell gene expression induced in the thymus,
GATA-3 is essential for the initial specification and survival of thymocytes in the earliest
T-cell developmental stages, then again for β-selection, and again for choosing the CD4+
and not the CD8+ cell fate during positive selection[85]. It continues to be important in
CD8+ cells, albeit at a lower level than in CD4+ cells[86]. RORγt turns on as the cells
pass β-selection into the CD4+ CD8+ (DP) stage, where it is crucial for maintaining
survival of cells awaiting any form of positive selection at all, long before effector
lineage is determined[87]. The gene expression patterns that depend on GATA-3 and
RORγt in these earlier stages have little to do with the gene expression patterns that they
govern in late effector T-cell development[39, 85]. Thus, developmental context dictates
the range of action that is open to these factors.
Transcription factor binding vs. transcriptional regulatory activity
Genome-wide analysis of transcription factor binding using chromatin immune precipitation
and deep sequencing (ChIP-seq) has revealed some unexpected general aspects of these
factors’ function. The numbers of genomic sites detectably bound by many transcription
factors greatly exceed the numbers of genes that are shown to be affected by gain or loss of
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the factors’ activities. Also, although binding sites are often clustered around genes that the
factor clearly regulates, they are also commonly found associated with non-responsive
genes. This means that binding (e.g. detected by ChIP-seq) cannot simply be assumed to be
functional. In fact, patterns of local occupancy can fail to predict function in both directions.
The “false negative” problem is that one can readily find genes that are affected by changes
in level of a transcription factor even though that factor appears to lack any binding site near
the gene’s promoter. The “false positive” problem is that many factors bind to a range of
genomic sites at which the nearest genes do not change expression in response to the factor.
The “false negative” problem can be explained by two kinds of mechanisms that are each
intrinsically interesting: an indirect gene network connection, or a distal cis-regulatory
element. If a regulated gene actually depends on an intermediate regulatory or signaling
gene that is truly a direct target of the factor of interest, then the regulated gene can be
affected by gain or loss of function of the factor of interest even if it is not a target itself.
This is not biologically insignificant but a clue to a major feature of developmental
control[28]. Gene-specific indirect effects, once dissected by epistasis tests, reveal large
sectors of gene network architecture.
In another source of false negative results, an affected gene apparently lacking a
transcription factor binding site can still be a direct target, if that gene has a distant cis-
regulatory element that lies outside of the search space assumed to belong to that gene. Even
if binding is not found in a region thought to be a gene’s enhancer, increasing evidence
suggests that genes can possess multiple potential distal elements rather than a single
enhancer. Some of these elements may simply appear to reinforce each other’s activity in the
cell types under consideration (“shadow” enhancers) while others are functionally quite
distinct[29]. Cis-regulatory elements for Gata3 and Bcl11b in mouse T-lineage cells have
recently been found in gene deserts 280 kb and 850 kb downstream of the genes,
respectively[30, 31]. Thus, extensive searches far beyond the 10-kb range, coupled with
strategies for evaluating function, are increasingly important for understanding of
mammalian gene regulation. To map promoter/enhancer interactions on such a large scale,
multiple new techniques have been developed to map long-range promoter/enhancer looping
based on crosslinking and deep sequencing[32–35], and these are beginning to provide
considerable information about the organization of active and inactive genes and their
regulatory elements in the nucleus[34, 35].
Many “false positive” signals really do not indicate function. A factor that engages in strong
interactions with other factors may join a bound factor ensemble even though a full
activating quorum has already been established without it (see below). Multiple-occupancy
regions, especially some extensive ones called “superenhancers”[36], are highly likely to be
important cis-regulatory elements[37–39], but it is not clear how many of the factors
involved in binding at such regions are really required for activity. When a factor is bound at
such a site, it may simply act as a marker for an active cis-regulatory element without being
an essential contributor. At the opposite extreme, certain factors that have the power to bind
directly to nucleosome-occupied DNA need not bind where other factors are engaged[21]. In
some cases they can establish occupancy at isolated sites in chromatin that have no potential
for functional activity. However, other suspected false positives are a consequence of the
Rothenberg Page 4
Trends Immunol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
way that transcription factor action interfaces with the chromatin regulatory state to affect
future action of other transcription factors at the site. A closer examination of the steps
toward cis-regulatory element activation suggests that factors can play certain roles through
isolated binding to nucleosome-packed DNA which may become important for later
transcriptional regulation, even if they do not correlate immediately with target gene
expression.
Target seeking: constraints of context and history
Factors like EBF1 and GATA-3 occupy ~1500–4000 sites in pro-B and -T cells, SCL(Tal1)
and Runx1 bind ~10,000–15,000 sites in early hematopoietic progenitors, whereas PU.1 and
Pax5 bind ~30,000–75,000 depending on cell type[18, 37, 38, 40–48]. Yet even those that
bind to many more sites reach only a fraction of the full spectrum of their potential sites in
the genome as defined by analysis of DNA sequence. A transcription factor is often able to
bind particular sites in one cell-type context that it cannot bind at all in another. The sites
bound by PU.1 are substantially different in macrophages than in B cells and in early T
cells[42, 43]. Pax5, which binds to a large number of sites in B-lineage cell genomes, binds
to a different spectrum of targets in pre- and pro-B cells than in mature B cells[47].
GATA-3, despite its reputation as a “master” regulator of the Th2 cell fate, is recruited to
very different genomic sites in developing T cells than in Th2 cells[41]. It even redeploys to
distinct patterns of occupancy during intrathymic development, between the early T-cell
developmental stages (ETP-DN2b) and the intermediate CD4+ CD8+ (DP) pre-selection
stage thymocytes[41, 42](Fig. 1). These redistributions are necessarily guided by partner
factors and/or underlying chromatin landscapes.
Sites for some transcription factors can be effectively occluded based on a cell’s
developmental history. A good example is the fate of exogenously transfected EBF1 in
EBF-negative hematopoietic and non-hematopoietic cell types[40]. EBF1 normally regulates
one set of target genes in B cells and another, completely distinct set in adipose (non-
hematopoietic) cells. When introduced into EBF-negative hematopoietic cells, exogenously
transfected EBF1 becomes bound to “B-cell gene” target sites where it induces activating
histone modifications. However, it does not reach these B-cell target sites at all if transfected
into EBF-negative non-hematopoietic cells[40]. Thus, earlier hematopoietic developmental
events must set a stage in which EBF1 can work to promote B-cell gene expression.
Similarly, exogenous PU.1 introduced into T-lineage cells occupies fewer sites than it
naturally occupies in myeloid cells[49]. In some cases the differential accessibility may
reflect the presence or absence of additional partner transcription factors, which allow
otherwise transient, undetectable interactions of the factor with DNA to be stabilized at
particular sites. In other cases, differential accessibility can reflect a barrier of closed
chromatin. In the earliest T-lineage cells, which do express PU.1 normally, PU.1 fails to
bind to sites with the repressive chromatin mark, H3K27me3, even when they are known
sites of PU.1 action in other cells[42]. On the other hand, a factor can be recruited to a new
spectrum of sites by the presence of other factors. Expression of factors such as EBF1,
Runx1, PU.1, or STAT factors in certain contexts can cause the redeployment of other,
previously expressed regulatory factors, to join them in multi-factor complexes at new
sites[18–20, 43, 48].
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Cis-regulatory elements enable transcription factors to act combinatorially
across time
Partner effects on transcription factor binding are in complete harmony with extensive
evidence that effects on gene expression are determined by combinations of transcription
factors, not by factors acting alone. Cis-regulatory elements, which represent clusters of
potential transcription factor binding sites, act as a scaffold to dictate the combinations of
transcription factors that will be needed to cross the threshold for exerting activity.
Transcription factor collaboration at these sites can be based on strong cooperativity for
DNA binding, where interactions with a partner factor can deeply influence a transcription
factor’s stability of DNA binding[50–54]. On some cis-regulatory elements, coordinate
occupancy by multiple factors appears to be required in order to assemble a stable ensemble
of binding factors at all. Such “enhanceosome” assembly is an elegant mechanism to ensure
“AND” logic for physiologically high-stakes gene activation pathways such as induction of
some cytokine genes[55]. However, functional cooperativity can also emerge at cis-
regulatory elements where transcription factors bind separately in time. For example, one
factor can bind initially as a “pioneer” and await the advent of others that eventually
complete the quorum for enhancer or promoter activity[22, 24, 48, 56, 57]. Thus, without a
needed partner, a factor may be unable to make a particular cis-regulatory element work
even when it does bind. Considerable recent work in several model systems has now defined
component steps that go into activating a cis-regulatory element, by combining evidence
from transcription factor binding analysis (ChIP-seq) with analyses of histone modifications
(ChIP-seq) and general DNA accessibility (DNase-seq, FAIRE, or restriction enzyme
accessibility assays)[21, 22, 58]. This process is summarized in Fig. 2.
For most of the genes used in lymphocyte development, the onset of expression involves
activation from a silent ground state (see Box 2). Generally the most cell-type specific,
developmentally dynamic chromatin modifications take place at enhancers (distal cis-
regulatory elements)(e.g. [42, 43]). Long before a gene’s expression the promoter may
already be marked by a histone “accessibility” mark (H3K4me2 or even H3K4me3,
emplaced by MLL histone methyltransferase factors)[42, 59, 60], although in these non-
expressing cells, if the promoter itself has CpG islands, it may initially be occluded with
repressive H3K27me3 histone marks (H3K27me3; see below). Such repression marks
persist by default but can readily be removed by transcription factor-recruited cofactors
when a gene is activated[42, 61]. At the ground state for enhancers, the DNA is often
unmarked but relatively condensed in nucleosomes, as defined by relatively poor DNase
sensitivity. The opening and activation process at the enhancer begins when certain
transcription factors are expressed, which are capable of binding to these nucleosome-
wrapped DNA sequences without impediment[58]. The binding of these “tier A” or
“pioneer” factors initially need not lead to any more detectable consequences, but it may
create a preferential recruitment site for other, “tier B” factors as they become available.
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Box 2
A complex regulatory baseline in hematopoietic precursors
Many of the genes activated in the T and B cell programs are expressed in a highly cell
type-specific way, beginning after the divergence of distinct types of partially restricted
hematopoietic progenitors. T-cell and B-cell regulatory genes like Bcl11b and Pax5 are
embedded in repressively H3K27me3-marked chromatin in hematopoietic progenitors
until they are activated[31, 42, 59, 60], and Bcl11b is extensively methylated across its
promoter and enhancer regions until T-cell development is under way[77]. These cases
suggest genuine epigenetic inaccessibility. The closed state of these genes may continue
or be reinforced in developmental lineages that do not turn them on, explaining why
Bcl11b in B-lineage cells and Ebf1 in T-lineage cells are sequestered in repressive
intranuclear domains[32]. However, the silence of these loci in multipotent progenitors is
obviously not permanent. This suggests that a tier A-type activity must be induced in
early specification of T and B lineage cells to begin activation of the appropriate genes.
Alternatively, combinations of factors that can collaborate in tier A/tier B fashion may
need to rise above some threshold concentrations, simultaneously within the same cells,
in order to be able to open up the regulatory elements of these genes.
In fact, there is indirect evidence that multiple factors that activate lineage-specific genes
are already present in hematopoietic precursors, even if they are not yet strongly or stably
enough expressed to coordinate an entire lymphocyte developmental program. Individual
uncommitted hematopoietic precursors are known to express low-level transcripts from
genes associated with several distinct lineages at once[88–91]. This phenomenon,
multilineage priming, does not embrace all the genes that will later be expressed as part
of the final differentiation programs; many remain silent. However, the genes being co-
expressed belong to the same developmental programs that these precursors may access,
implying that some transcription factors that could drive these programs are already
present in sufficient concentration to promote at least intermittent target transcription.
What makes multilineage priming-associated genes more accessible than Bcl11b and
Pax5? Some lineage-associated genes may initially reside in open chromatin, awaiting a
positive regulator. Many have accessible marks (H3K4me3) at their promoters even in
hematopoietic stem cells[59]. More tightly regulated genes may require a lineage-specific
tier A factor. Another difference may reflect the constraints of transcription factor
collaboration across time: how strictly tier A/ tier B factor activities must be coordinated
to open an enhancer element. Recent single-cell gene expression analyses show that
hematopoietic multilineage progenitors are heterogeneous in their expression of key
transcription factors[92–94]. The range of phenotypes suggests that transcription factor
expression could vary dynamically in these precursors even when the same general
combinations are present, promoting the same fates (cf. [95]). Genes with cis-elements
where tier A factors can wait for tier B recruitment can easily be turned on. Genes with
elements requiring coincident binding by two or more tier A/B factors may not be
effectively activated until the gene regulatory network that mediates differentiation
stabilizes expression of these factors at adequate levels.
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Either tier B factors or the initial tier A factors, depending on the factors and the cis-
regulatory element, can then begin opening the nucleosome packing around the binding
sites[58, 62]. As nucleosomes are pushed apart, the element can become DNase
hypersensitive, and usually the histones are modified to H3K4me1 or further modified to
H3K4me2, using MLL histone methyltransferases[18, 19, 43, 44, 63](Fig. 2). This is a
critical tipping point in the progression to enhancer activity, but even so, it can occur long
before the enhancer is actually active. Note that tier B factors themselves need not be
expressed after tier A factors; they can actually pre-exist in the cell. However, they do not
come to these sites until the tier A factor creates a beachhead, and this is detected as
recruitment or redeployment of the tier B factor. Examples include the impact of EBF1
expression on E2A binding, or the impact of Runx1 expression on SCL/Tal1 binding[19,
48]. These initial binding events can occur coordinately, in which case the cooperative
binding of two classes of factors enhances the binding of both. But the tier A/tier B
distinction is worth making because in other cases, single occupancy can exist for a long
time before the recruitment of second-tier factors can trigger full enhancer accessibility[18].
The modified histones induced by tier A/B factor binding indeed appear to mark “poised
enhancers”, sites of long-term preferential accessibility[18, 64]. To get from this point to
positive regulatory activity of the enhancer, however, usually requires binding of yet more
factors (or possibly removal of obstructive ones). With “tier C” factor addition, then, the
element suddenly emerges as an “active” enhancer[24, 44, 65], characteristically marked
with H3K27Ac. This results as the assembly of transcription factors achieves a quorum for
recruitment of the EP300 (p300) or Crebbp (CBP) transcriptional coactivator complexes,
which acetylate local nucleosomes at the H3K27 sites[65, 66], in what may be a hit-and-run
process[63]. This is well coordinated with enhancer looping to a cognate promoter via the
Mediator complex, and the target gene finally responds to the accumulation of events that
have activated its enhancer.
Because binding of different factors is so affected by binding of prior factors in this process,
the transcription factor that appears to correlate best with the activity of the target gene
depends on which type of factor is limiting in the cell. This is not a biochemical question so
much as a developmental programming question. In fact, a given factor can play different
roles at different cis-regulatory elements. For example, in myeloid cells, development is
dependent on C/EBP factors and PU.1, and these can each act as initial pioneering factors
for the other’s recruitment at different sites[43]. But the actual transcription onset depends
on the addition of the tier C factor(s) to the tier A/tier B engaged complex. Thus, if the tier C
factor(s) is rate limiting, and the binding of the tier B factor(s) is always saturated, tier C
may look like the “master regulator”. But if the tier B factor(s) is not present, then there may
be no open chromatin at the enhancer for the tier C factor(s) to bind to, and thus a factor
playing the tier B role may appear more dominant.
An asymmetry of understanding: the obscurity of repression
Cis-regulatory elements also include the sites where repression complexes are assembled.
Repression is less well understood in general. However, most transcription factors can be
bifunctional, participating in ensembles that recruit coactivators or corepressors depending
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on the overall architecture of transcription factors organized by their DNA binding at a
given cis-regulatory element. At present, there is only sparse evidence about how many
copies of a repressor or how many different kinds of binding factors at a given site are
needed to establish repression. Converting an active cis-regulatory element to a repressive
one usually involves local expulsion (or cell-wide loss) of positive regulators, with loss of
histone acetylation and often reduced H3K4 methylation as well[46, 67]. These elements
also commonly become less DNase-accessible as the repression process compacts the
nucleosomal array[68]. Unfortunately for systematic analysis, these elements thus become
less detectable against the background of neutral DNA. Some repressed elements become
modified by Polycomb Repressive Complex 2 to add H3K27me3 marks, especially elements
near repressed CpG-island promoters[67, 69, 70]. But this process is often a slow step that
occurs long after transcription of the repressed gene has been shut off[42], and therefore
gives only indirect evidence of the factors that caused repression and the critical sites
through which they worked. A better understanding of repression is crucial for explaining
commitment (Box 3).
Box 3
Two problems for the future
• Enhancer-promoter interaction rules need elucidation. Enhancers can be
detected readily when changes in their histone marks correlate dynamically with
those of a neighboring gene[31, 65], but this matching is extremely difficult
when multiple genes lie between the element and the promoter it actually
regulates. Still to be defined is how specific enhancers and their “cognate”
promoters identify each other across distances that can reach multiples of 100 kb
of DNA; how this traffic is regulated; and how many distinct enhancer elements
are actually communicating with a promoter at any given time to control its
activity level. New crosslinking and deep sequencing variants of chromosome
conformation capture technology like 4-C, 5-C, hi-C and ChIA-PET offer some
promise for addressing the mapping part of this question[32–35]. At the same
time, insight into the temporal dynamics of enhancer-promoter communication
may begin to emerge through live fluorescent monitoring of single-cell gene
expression level fluctuations within a developmentally equivalent population.
Determining how much of gene expression is steady and how much results from
“bursts” alternating with silence may help to establish some boundary values for
the stability or instability of promoter-enhancer associations. The technologies
that must converge to answer this question are in rapid development.
• Repression is central to the establishment of a coherent developmental identity,
and it plays an even more prominent role in the pathway toward T-cell
development than might have been expected[42]. However, at a genome-wide
level the mechanisms used for different kinds of repression are poorly defined:
in particular, the distinction between temporary “repression” and permanent
“silencing” is currently impossible to recognize. DNA methylation, at least as
detected with current methodology, does not appear to be a barrier to gene
activation[96] and is easily removed, e.g. in cases of the T-cell regulatory genes
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Tcf7 and Bcl11b which are demethylated at multiple sites as they become
active[77]. Despite the usefulness of H3K27me3 to denote one form of
repression, genes with H3K27me3 marks need not be profoundly repressed. For
example, the CD4+ specification factor Zbtb7b (Th-POK) is active in the earliest
T-cell precursors but silenced with H3K27me3 marking during commitment
[42], only to be reactivated a few stages later during positive selection[97]. It
can be difficult to locate the DNA target sites where critical repressive
interactions are taking place, since in many cases, repression leads to a
disappearance of transcription factor binding as well as loss of active chromatin
marks and DNase accessibility[47, 67]. This can be a consequence of chromatin
condensation machinery, possibly combined with intranuclear
compartmentalization[32, 84, 98]. To improve understanding of these
mechanisms, repression may be best dissected by taking advantage of the
developmental kinetics of the regulatory change, to catch factors in the act of
imposing the repressed state.
Within the cis-regulatory module: strict ordering, late arrival, strong impact
If most active enhancers are sites not for binding of single factors but for binding of large
ensembles of factors[37–39], it is easy to see how their collective impact to displace
nucleosomes could establish a “virtuous circle” for enhancer activity. At the same time,
however, this group action can obscure the logic of what each factor is truly adding to the
activity of the cis-regulatory element. Thus, it has been illuminating to study two elegantly
documented cases in mature CD4+ T cells where it is clear that collaborating transcription
factors act in a particular, strict temporal relationship in order to activate or repress their
target genes correctly. These factors clearly do not act on the tier A level, but as quorum-
completing tier C or late tier B factors that associate with already DNase hypersensitive,
H3K4me1-marked regions to determine the output regulatory function of these elements.
Conventionally, Th1 and Th2 cells are thought to have their function determined by T-bet
and GATA-3, respectively, sometimes called their “master” regulators (Box 1)[9, 24, 25]. In
fact, input from IL-12 via STAT4 (or IFNγ via STAT1) is also crucial for Th1 development,
and input from IL-4 via STAT6 is needed for Th2 cell development. The respective STATs,
which translocate to the nucleus only when these cytokine signals are present, are known to
provide viability or activation maintenance in a general sense. They also play roles in
upregulating T-bet or GATA-3 initially, but their functions are often imagined in supportive
roles only. Now, however, new evidence demonstrates that the STAT factors act much more
pervasively to control the entire program of gene expression in their respective T helper
subsets[71]. Despite sustained differences in T-bet and GATA-3 expression between Th1
and Th2 differentiated cells, there are minimal differences between them in terms of the
H3K4me1 modification states of sequences across the genome. Regions that will become
both Th1-specific and Th2-specific gene enhancers are found equally marked by tier A/B
processes in both cell types. However, conversion of any of these Th1 or Th2-specific
enhancers to “active” status by recruitment of EP300 depends on the further binding of
appropriate STAT factors (STAT4 or STAT6) in response to current cytokine signaling.
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This is the step that determines the activity of the neighboring/associated/cognate gene.
Lineage-inappropriate genes also lose EP300 from their enhancers in a STAT dependent
way.
The structural requirements for enhancer activation at many of these cis-regulatory regions
reveal hierarchical roles of different transcription factors in successive stages of enhancer
activity regulation. A major lesson in this work is that STAT4 and STAT6 have a much
larger impact on recruiting EP300 than the “lineage determining factors” T-bet and
GATA-3[71]. T-bet and GATA-3 recognition motifs are found enriched in the same Th1
and Th2-specific enhancers that are activated by STATs, although unfortunately it is not
clear whether T-bet and GATA-3 binding is actually stable without STAT co-occupancy at
these sites. Because STAT activity is needed to turn on T-bet and GATA-3 during Th1 and
Th2 differentiation, the STAT mutants themselves could suffer from compound defects.
However, the relative roles of these factors have been revealed in powerful add-back
experiments to complement the STAT knockout defects. For most of the Th1- or Th2-
specific enhancers, the requirement for STAT activation to induce EP300 recruitment to
these H3K4me1-marked elements cannot be bypassed by forced expression of T-bet and
GATA-3. Therefore the sequences of these Th subset-specific enhancers enforce the
requirement for current cytokine signaling, through engagement of the correct STAT, in
order to trigger target gene expression.
A second example reveals the opportunistic modus operandi of the transcription factor
Foxp3, which is often considered the “master” regulator for Treg cells[72, 73]. Quite
unexpectedly for such a potent factor, when its binding distribution was evaluated, it turned
out that Foxp3 cannot find its own target sites in the genome. It depends completely on the
presence of other factors at an enhancer to enable its own binding and function and appears
completely unable to get to DNA sites by itself[74]. Fortunately, Foxp3 is not required for
viability of naive T cells, and so cis-regulatory element activity measured by DNase
hypersensitivity can readily be compared between Foxp3+ induced Treg cells and Foxp3-
negative cells that could represent their precursors. This analysis shows that all the sites
Foxp3 binds to are already DNase hypersensitive in Foxp3-negative cells. Ultra-deep
sequence analysis of the DNase hypersensitivity patterns in these samples has made it
possible to map individual transcription factor contacts within active enhancers in the
presence and absence of Foxp3. In the fine structure of DNase protections within the core of
the DNase hypersensitive regions, each 10–15 bp feature represents a kind of protective
shadow diagnostic of transcription factor binding at that particular site[75, 76]. This has
revealed not only that Foxp3 binding causes no change in DNase hypersensitivity, but also
has identified the exact motifs within those cis-regulatory regions that are bound by
transcription factors with and without Foxp3[74]. Foxp3 binding site selection to the
genome does not involve recognition of its own cognate motifs, but rather, sites where other
factors are already bound in an unchanging way. What Foxp3 affects is the functional
consequence of these transcription factors’ binding.
Two classes of these sites contrast in terms of the likely order of action of the site-
determining factors and Foxp3. The most common sites are engaged by Runx and Ets family
transcription factors. Members of these families should be active in all T cells and could be
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playing classic tier A/B roles. However, other Foxp3 recruitment sites include sites for
NFAT, a factor that only enters the nucleus when Ca2+ release activated by T-cell receptor
(TCR) signaling causes its translocation (somewhat analogously to STAT activation by
cytokine receptors). In this case, Foxp3 already present in the nucleus presumably
piggybacks onto newly immigrated NFAT during TCR stimulation. This brings Foxp3 to
sites where NFAT could normally mediate Ca2+ dependent gene activation, which Foxp3
then blocks. The only places where FoxP3 binds to Forkhead sites that ought to be its
cognates are where it can displace a fellow family member, FoxO1, which had been acting
as a tier A/B pioneer factor. These again are preferentially sites where Foxp3 represses, i.e.
by reducing the positive activity that the FoxO1 had formerly provided[74]. Thus, despite its
potency at transforming T-cell function, Foxp3 cannot dictate cellular properties through its
own DNA binding specificity, but only modify them within boundaries established by the
factors that determine that cell’s open enhancer landscape.
Creating the ground state for lymphocyte identity
Both of these examples reflect the importance of the prior enhancer accessibility landscape,
but only hint at how it is established. The pre-marking mechanism has been studied very
little to date because it needs to be studied longitudinally across a developmental process,
focusing not only on the cells of ultimate interest but also on purified cells in successive
precursor stages. Early T cell development provides a rare opportunity to catch sight of the
process through which the regulatory landscape around many lymphoid development genes
is changed from a progenitor-like state to a lineage-specified T-cell state. Because of the
fine-scale dissection of stages that is possible in this system, some initial characterization is
now in hand[42]. T-cell precursors transition from multipotency to commitment from the
Early T cell Precursor (ETP) to the DN2b/DN3a stages (Fig. 1), before the TCR genes
become rearranged and thus before any TCR-dependent selection[3]. During commitment,
there are dynamic histone marking changes across multiple genetic loci[42, 60], coupled
with major transformations of DNA methylation status at key sites[77]. Although the
specific roles of individual transcription factors in this process are still being defined, the
“crime scenes” of multiple distinct regulatory events can be mapped clearly. From stage to
stage, specific cis-regulatory elements change from latent (or silent) to active modification
states, while new repressive marks are deposited on sites that were recently marked as
enhancers, after the positive inputs have been lost[42, 60, 78]. By following H3K4me2
across the genome from stage to stage, it is possible to detect first appearance of specific
marked distal elements, presumably at the tier B stage, that immediately foreshadow the
activation of linked, key developmental genes. These marking changes are functionally
significant: for example, removal of H3K27me3 and appearance of H3K4me2 at a
previously unknown, distal region in parallel with those at the promoter of the tightly
regulated Bcl11b gene has revealed a novel, far-distant enhancer for this gene[31]. Such
results in aggregate should provide initial guidance to help locate many developmentally
significant cis-regulatory elements for T-lineage cells.
Like many hematopoietic cells, T-lineage cells preferentially use enhancers that are rich in
sites for Ets-family and Runx family transcription factors regardless of what other factors
bind there. This is not only the case for Tregs. In Th1 and Th2 cells, most active enhancers
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whether shared or subset-specific are enriched for Runx motifs[71]. Basic helix-loop-helix
(bHLH) factors like E2A and HEB tend to bind to Ets or Runx motif enriched sites in B and
T cell precursors[19], and an Ets family motif was as enriched as the GATA motif in a
sample of GATA-3 binding sites in early T cells[42]. These families of factors are indeed
expressed throughout T cell development, but they cannot be simply responsible for defining
T-lineage specific sites since their roles go back to multipotent hematopoietic progenitors.
Multi-factor ChIP-seq studies of primitive multipotent hematopoietic progenitors have
repeatedly shown enhancers for the signature genes of these cells to be marked by the
clustering of bHLH, GATA, Ets, and Runx family factor binding. T lineage cells share with
hematopoietic precursors expression of factors of all of these families. Although individual
Ets-family members change expression, the Ets1/Ets2/Fli1/Erg subfamily (with nearly
identical binding specificities) is consistently represented by at least one member, from stem
cells to mature T cells[79, 80]. Thus, such Ets and Runx factors are likely to play a tier A
hematopoietic role, but not a role to define the lineage-specifically poised status of
developmentally emergent enhancers.
What appears unexpectedly prominent during lineage commitment is extinction of
previously expressed regulators. As the cells lose multipotentiality, the regulatory genes that
were active in the initial T-cell development stages are shut off and then silenced[42, 79–
81]. The cells lavish considerable regulatory complexity on this task, imposing repression on
different genes in at least three waves from ETP stage to the β-selection checkpoint, and
utilizing a variety of different repressive mechanisms[42]. PU.1, the abundant factor
commonly playing tier A/B roles in progenitors, is one of the factors eliminated during
commitment. As the cells cross the β-selection boundary and develop to the CD4+ CD8+
(DP) stage, there is a significant deposition of H3K27me3 marking on promoters of
numerous regulatory genes that were active in initial stages, even though the silencing of
transcription and loss of positive enhancer inputs had occurred earlier[42, 60]. By the time
the cells reach DP stage, the progenitor-associated regulatory genes that have CpG island
promoters are already fully silenced with H3K27me3 marks[42, 82, 83]. The loss of these
foundational regulators not only removes factors that might recognize specific DNA motifs,
thus closing off certain elements that required their occupancy, but also may shift the status
of the transcription factor complexes that remain. For example, although the crucial bHLH
factor E2A remains present throughout, its involvement probably shifts from membership in
SCL (Tal1)/E2A or Lyl1/E2A heterodimers to functionally different E2A/HEB and
E2A/E2A homodimers as first Tal1, then Lyl1 are repressed. Thus, certain accessibility
barriers are already in place, a large part of establishing what the later regulatory state of
mature naive T cells will and will not allow.
Concluding Remarks and Outlook
Transcription factors have great power over cell function through gene regulation, but they
cannot operate dictatorially outside of a regulatory state context. They must work
combinatorially with other factors, whether the contributions of those other factors are
simultaneous or not. The ability of transcription factors to modify nucleosomal packing and
recruit local histone modifications gives them a way to propagate their influence across
time. This is particularly important in a hierarchical, prolonged developmental process like
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hematopoiesis which re-uses similar transcription factors repeatedly to activate divergent
gene programs. Fortunately, we can now use some of these chromatin modifications to
detect when prior action of a transcription factor ensemble has altered the thresholds for
local action by new factors. By considering the multiple tiers of function that a transcription
factor can provide at a given cis-regulatory element, it is possible to understand how gene
expression programs that differ intricately between lymphocyte subsets can be established
by factors whose individual expression patterns and even whose binding patterns appear to
be too broad.
The gene networks that control T-cell development are much deeper than a single tier of
gene regulation, and the crucial frontier for the future will be to use these new tools to
understand how the regulators themselves are controlled at successive stages. This will
involve more elucidation of distant cis-regulatory region interaction with target genes, of the
rules for positioning genes in permissive and repressive nuclear compartments[84], and a
much clearer understanding of repression. However, the pathway to understanding this
process is becoming clear and a causal, molecular mechanism for the levels of T-cell
development is coming within reach.
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Highlights
• Multi-tiered action of transcription factors remodels the chromatin landscape
• Differential chromatin access and partner factors bias binding site choice
• Powerful transcription factors can work by modifying effects of other factors
• Selective transcription factor silencing shapes the regulatory state in early T
cells
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Figure 1. Decision points and transcription factors in T cell development
A simplified schematic of T-cell development is shown with the main stages of development
within the thymus labeled, key checkpoints and choice points indicated in red labels, and
selected transcription factors indicated at major points when they must act. The figure shows
diagrammatically which events occur in the thymus and which ones occur either
prethymically or in the periphery after T-cell maturation. Major decisions and stages that
depend on GATA-3, PU.1, RORγt, T-bet, Foxp3, and multiple STAT factors are indicated.
Runx, Ets, and bHLH family factors have continuing roles throughout these events, although
the precise family members involved and their roles can change. T-lineage entry: migration
of cells to the thymic microenvironment, which is rich in Notch-activating molecules.
Commitment: relinquishment of potential to give rise to anything except T cells. β-selection,
positive selection: two stages of TCR-dependent developmental checkpoint where cells with
failed TCR status will die. Also shown are the stages when continuing Notch pathway
signaling in the thymus is critical for T-cell specification: these are stages when the cells are
“double negative”, i.e. lacking CD4 and CD8 expression. The stages within this immature
series are ETP (Early T-cell Precursor), c-Kit++ CD44+ CD25−; DN2a, c-Kit++ CD44+
CD25+; DN2b, c-Kit+(intermediate) CD44+ CD25+; DN3a, c-Kit− CD44− CD25+. TCR gene
rearrangement does not result in expression of a TCRβ chain until the DN3a stage, but this
triggers β-selection. The cells quickly downregulate CD25 and upregulate CD8 and CD4
through the series of stages shown as DN3b, DN4, ISP in transition to “DP”, or CD4+ CD8+
double-positive. These cells continue TCR gene rearrangement until they finally express
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TCRαβ. They are subject to stringent TCR-based MHC restriction and selection and only a
minority are allowed to mature as CD4 SP or CD8 SP cells (Positive selection, CD4/CD8
choice). For simplicity, alternative intrathymic fates such as TCRγδ cells, invariant NKT
cells (iNKT) or natural Tregs (natural Tregs) are not shown. Four major types of effector
subsets of CD4+ cells, which develop from mature CD4 SP cells in the periphery, are
shown, with some of the transcription factors that play major roles in their development.
Despite the clear distinctions between the regulatory programs of these effector subsets, they
remain conditionally plastic depending on environmental signals. Gray dashed-line arrows
indicate several well-established options for interconversion. This feature contrasts the
effector cell lineage decisions with the decision to commit to T-cell fate, which is
irreversible.
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Figure 2. Multiple tiers of transcription factor action generate an active enhancer
The figure shows three kinds of transcription factor occupancy that can have distinct effects
on the activity of an enhancer element. The steps in converting a closed, silent cis-regulatory
region to an active enhancer are shown for an element in which three factors (or groups of
factors) act in sequence. Only the Tier A factors are capable of recognizing their sites in the
DNA from a compact chromatin configuration. Whether or not the Tier A factors
themselves recruit the enzymes that mark local histones as “accessible”, however, they make
it easier for Tier B factors to bind. Tier B factors are those that elicit activating histone
marks and displace nucleosomes to create a DNase-accessible site. Note that the effect of
Tier B occupancy is to create a small “volcano”-like shape of histone modification
consisting of a wide, hollowed-out H3K4me1 peak with a narrow, cratered peak of
H3K4me2 in its center. Still, despite this modification, the cis-regulatory element may not
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be active yet. Then, as Tier C factors arrive and bind via DNA and/or protein-protein
interactions, a quorum is finally complete for the recruitment of the histone acetyltransferase
EP300. Tier C factors may bind DNA directly or, as in the case of Foxp3, can determine the
functional output of an enhancer even without extensive DNA contact. The large EP300
protein catalyzes modification of proximal histones to H3K27Ac forms and completes the
activation of the cis-regulatory element. Whether or not the EP300 remains associated at the
site, these fully activated, occupied elements are now competent to interact with the
appropriate transcription start site to enhance transcription.
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